Cytometry Part B-Clinical Cytometry

Papers
(The TQCC of Cytometry Part B-Clinical Cytometry is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Issue highlights—January 202540
Mass cytometric single cell immune profiles of peripheral blood from acute myeloid leukemia patients in complete remission with measurable residual disease35
34
An uncommon case of acute megakaryoblastic leukemia with DDX3X::MLLT10 fusion gene32
Erythroid side scatter: A parameter that improves diagnostic accuracy of flow cytometry myelodysplastic syndrome scoring26
The role of the primitive marker CD133 in CD34‐negative acute myeloid leukemia for the detection of leukemia stem cells21
20
Issue Information20
Standardization of flow cytometric detection of antigen expression18
Issue highlights—September 202318
Addition of CD14 improves discrimination of lymphocytes in the TBNK phenotyping panel18
Phenotype and oxidative burst of low‐density neutrophil subpopulations are altered in common variable immunodeficiency patients15
Issue Information15
Frequency and stability of populations of CD4+ and CD4+CD25+Foxp3+CD127lo Treg in healthy adults defi14
A 20‐color 21‐antigen flow cytometric assay for disease monitoring of T‐cell lymphoblastic leukemia14
Machine learning optimized multiparameter radar plots for B‐cell acute lymphoblastic leukemia minimal residual disease analysis14
14
Utility of leukocyte‐associated immunoglobulin‐like receptor‐1 (CD305) in flow cytometric detection of minimal bone marrow involvement by B‐cell non‐Hodgkin lymphoma14
Defining atypical chronic lymphocytic leukemia for reproducible diagnosis: implications of the work by Wang et al.13
Validation of a new multiparametric protocol to assess viability, acrosome integrity and mitochondrial activity in cooled and frozen thawed boar spermatozoa13
Issue Information12
Abnormal B‐lymphoblasts in myelodysplastic syndromes and myeloproliferative neoplasms other than chronic myeloid leukemia11
CD133 in T‐lymphoblastic leukemia is preferentially expressed in early T‐phenotype (ETP) and near ETP subtypes11
Issue Information10
Issue Information10
ROR1 expression in mature B lymphoid neoplasms by flow cytometry10
Issue Information10
Issue Highlights—January 202210
Converting an HLA‐B27 flow assay from the BD FACSCanto to the BD FACSLyric10
Increased TOX expression concurrent with PD‐1, Tim‐3, and CD244 expression in T cells from patients with acute myeloid leukemia10
Whole blood no‐lyse no‐wash micromethod for the quantitative measurement of monocyte HLA‐DR9
Integration of T‐cell clonality screening using TRBC‐1 in lymphoma suspect samples by flow cytometry9
9
SingletSeeker: An unsupervised clustering approach for automated singlet discrimination in cytometry8
Alignment, segmentation and neighborhood analysis in cyclic immunohistochemistry data using CASSATT8
Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS‐Flow 8
Performance of a novel eight‐color flow cytometry panel for measurable residual disease assessment of chronic lymphocytic leukemia8
Quick identification of target antigens by tissue flow cytometry for CAR‐T therapy in B‐cell malignancies7
Correction to “Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International 7
Appropriate interpretation of TRBC1‐dim positive subsets in T‐cell immunophenotyping by flow cytometry7
Summary of validation considerations with real‐life examples using both qualitative and semiquantitative flow cytometry assays7
Anti‐CD38 VHH antibody (JK36) reliably detects CD38 yet uncovers CD38 downregulation in a subset of daratumumab‐treated multiple myeloma patients7
International Clinical Cytometry Society 2023 workload survey of clinical flow cytometry laboratories6
Monocyte maturation pattern by flow cytometry expression of CD64, CD300e, and CD14 correlates to presence of myeloid neoplasm and helps identify blast equivalents in t6
Enhancing HLA‐B27 antigen detection: Leveraging machine learning algorithms for flow cytometric analysis6
6
Ad hoc antibody modification of a validated flow cytometric immunophenotyping panel—recommendations and safeguards for clinical laboratories6
6
6
Issue Information6
Monocyte HLA‐DR expression as an enrollment biomarker in sepsis clinical trials: Evaluation of two sampling tubes and definition of respective clinical thresholds5
Remembering Dr. Bruce H. Davis: A passionate leader in clinical flow cytometry5
The patterns and diagnostic significance of the lack of surface immunoglobulin light chain on mature B cells in clinical samples for lymphoma workup5
Prospective validation of podoplanin expression as a diagnostic biomarker of acute promyelocytic leukemia5
Flow cytometric analysis of myelodysplasia: Pre‐analytical and technical issues—Recommendations from the European LeukemiaNet5
Editorial on IVD cellular assay validation5
Clinical significance of end of induction measurable residual disease monitoring in B‐cell acute lymphoblastic leukemia: A single center experience5
Automated analysis of flow cytometry data with minimal training files: Research evaluation of an elastic image registration algorithm for TBNK, stem cell enumeration, and lymphoid screening5
Issue Highlights—July 20225
Intraoperative flow cytometry in detecting free carcinoma cells in peritoneal lavage fluid of gastric carcinoma cases5
5
Extranodal NK/T‐cell lymphoma with isolated central nervous system relapse: A defiant disease and the role of flow cytometry in monitoring5
Possible alternative strategies to implement basophil activation testing in multicentric studies5
Implementation of beaker CP for flow cytometry: Workflow optimization and integration at Stanford Health Care5
Glucose‐6‐phosphate dehydrogenase deficiency detection using fluorocytometric assay: Evaluation after 1 year of clinical implementation5
0.097067832946777